Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
15 April 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Unravelling the heritability of triglycerides and coronary riskRead more...

Driven by genetics, elevated triglycerides, a marker of triglyceride-rich lipoproteins and their remnants have regained the focus of attention.
Since 2013, studies have provided consistent evidence for specific loci with an exclusive effect on triglycerides, notably variants associated with APOA5 and APOC3; these were also associated convincingly with clinical coronary artery disease and subclinical atherosclerosis.
However, further elucidation of the heritability of triglycerides and their causality with cardiovascular disease was needed.
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
15 April 2016

VOYAGER highlights need for additional therapy targeting elevated triglycerides in statin-treated patientsRead more...

Despite intensive statin therapy to lower elevated LDL-C levels a high residual cardiovascular risk persists. There is now accumulating evidence to support elevated triglycerides (a marker for triglyceride-rich lipoproteins and their remnants) as an important contributor to this residual risk,1,2 as discussed in Call to...
focus on...
15 April 2016

Genetic studies indicate potential of ANGPTL4 inhibition for lowering triglycerides and preventing coronary diseaseRead more...

Growing consensus, supported by epidemiologic, mechanistic and genetic studies, supports a causal role for elevated triglyceride-rich lipoproteins and their remnants (for which plasma triglycerides are a marker) in atherosclerotic cardiovascular disease. Findings from Mendelian randomization studies (a type of ‘natural’ randomized trial), which capture the...
recent publication

Not all HDL cholesterol is goodRead more...

Low plasma concentration of high-density lipoprotein (HDL) cholesterol is recognized...
recent publication

VADT: Higher HDL cholesterol decreases risk of progression of diabetic retinopathyRead more...

Continuing on the HDL theme, this report from the Veterans...
recent publication

Low HDL cholesterol and risk for chronic kidney diseaseRead more...

Low HDL cholesterol has already been shown to be an...
recent publication

Isolated low HDL cholesterol prevalent in PeruRead more...

Isolated low plasma HDL cholesterol concentration was the predominant lipid...
recent publication

HDL cholesterol implicated in hypertensionRead more...

Both low and high HDL cholesterol concentration was associated with...
recent publication

Legacy effects of statins: WOSCOPSRead more...

Long-term follow-up of the West of Scotland Coronary Prevention Study...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.